RNA interference: new therapeutics in allergic diseases.
Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development.
Lee
Chen-Chen
CC
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chiang
Bor-Luen
BL
D000818:Animals; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D035683:MicroRNAs / Q000627:therapeutic use; D034622:RNA Interference; D034741:RNA, Small Interfering / Q000627:therapeutic use*
D035683:MicroRNAs; D034741:RNA, Small Interfering